- Clinical Expertise
- Liver Cancer
- Board Certifications
- Internal Medicine
- Hematology
- Oncology
- Appointments
- Assistant Professor of Clinical Medicine, Columbia University Medical Center
- Education
- B.A., 1991, Brown University, Providence, RI
- M.D., 1997, University of Massachusetts Medical Scoool, Worchester, MA
- Internship & Residency
- Internal Medicine, 2007, New York-Presbyterian Hospital, New York, NY
- Fellowship
- Hematology/Oncology, 2003, New York-Presbyterian Hospital, New York, NY
- Oncology, 2002, Dana Farber/Brigham and Women's Cancer Center, Boston, MA
Abby Siegel, M.D.
NEW PATIENTS TEL (212) 305-5098
ADMINISTRATIVE OFFICE TEL (212) 305-9781
FAX (212) 305-4343
- OUTPATIENT OFFICE LOCATION
- Irving Pavilion-IP Garden
- 161 Fort Washington Ave at W 165th St..
- PHYSICIAN SUMMARY
- Abby Siegel, M.D. is an Assistant Professor of Medicine at the New York-Presbyterian Hospital-Columbia University Medical Center. Dr. Siegel cares for patients with gastrointestinal cancers, with an emphasis on liver, biliary, and colon cancers.
Dr. Siegel received her B.A. degree from Brown University. She graduated A.O.A. from the University of Masachusetts Medical School, and received her Internal Medicine training at New York Presbyterian Hospital-Columbia University Medical Center. She completed fellowship training in hematology and oncology at the Dana Farber Cancer Center and at New York Presbyterian Weil-Cornell Medical Center. She is involved in studies looking at new biologic agents for liver cancers, and novel treatment strategies, such as liver transplantation, for cholangiocarcinomas. She also conducts research in treatment outcomes for liver cancers, and teaches on the solid tumor service.
Dr. Siegel is involved in clinical and translational work in hepatobiliary malignancies. She has two main areas of interest. The first is in the evaluation of targeted therapies in hepatobiliary malignancies. She is currently the overall Principal Investigator of the Phase II Consortium Trial of bevacizumab in HCC, and will be the nationwide PI of a novel FGF inhibitor for HCC opening in the fall. She is developing a protocol with the Mayo Clinic to enhance liver transplantation for those with cholangiocarcinomas. Her other area of interest is in health outcomes in HCC. She had published or submitted 4 manuscripts in the last two years looking at various issues related to outcomes for those with HCC. She is currently completing her Master’s degree in biostatistics to further these goals.